Lumosa Therapeutics Co., Ltd.
6535
Rank in Stocks
#13700
Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company,... Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has completed Phase III clinical trials for the management of severe post-operative pain. The company's pipeline also includes LT3001, currently in Phase II for treating acute ischemic stroke; LT5001, which has finished Phase Ib trials for uremic pruritus; and LT2003, an oncology drug candidate in its preclinical development stage. Founded in 2000, Lumosa Therapeutics maintains its operational base in Taipei.
Share Price
$2.21
Last synced: 2026-11-10
Market Cap
$370.16M
Change (1 day)
1.40%
Change (1 year)
-63.37%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Lumosa Therapeutics Co., Ltd. (6535)
Category
Healthcare
Operating Margin for Lumosa Therapeutics Co., Ltd. (6535)
Operating Margin as of November 2026 TTM: -882.81%
According to Lumosa Therapeutics Co., Ltd.'s latest financial reports, its current operating margin (TTM) is -882.81%. At the end of 2025 the company had an operating margin of -930.73%.
Operating Margin history for Lumosa Therapeutics Co., Ltd. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -882.81% | -5.15% |
| 2025 | -930.73% | 2.09% |
| 2024 | -911.64% | 38.14% |
| 2023 | -659.96% | -42.53% |
| 2022 | -1,148.26% | -53.67% |
| 2021 | -2,478.27% | 57.10% |
| 2020 | -1,577.55% | 1,709.74% |
| 2019 | -87.17% | -61.74% |
| 2018 | -227.83% | -58.92% |
| 2017 | -554.56% | -74.16% |
| 2016 | -2,145.95% | -19.56% |
| 2015 | -2,667.93% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.83% |
US
|
|
| 25.57% | -100.03% |
AU
|
|
| 31.23% | -100.04% |
BE
|
|
| 29.35% | -100.03% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Lumosa Therapeutics Co., Ltd.'s operating margin
What is Lumosa Therapeutics Co., Ltd.'s operating margin?
Lumosa Therapeutics Co., Ltd.'s operating margin is -882.81%, as of Nov 2026.
What was Lumosa Therapeutics Co., Ltd.'s operating margin in 2025?
In 2025, Lumosa Therapeutics Co., Ltd.'s operating margin was -930.73%, compared with -911.64% in 2024.
How has Lumosa Therapeutics Co., Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Lumosa Therapeutics Co., Ltd.'s operating margin was highest in 2023 (-659.96%) and lowest in 2021 (-2,478.27%).
How does Lumosa Therapeutics Co., Ltd.'s operating margin compare with similar companies?
Lumosa Therapeutics Co., Ltd.'s operating margin (-882.81%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.